J.Molner
Press release from First North

J. Molner AS Announces Historic Milestone: Receives Health Canada Approval for its First Drug, Norepinephrine Bitartrate Injection

Tallinn, 2023-06-08 12:44 CEST -- J. Molner AS, an Estonian pharmaceutical company, is pleased to announce that it has received its first-ever new market approval from Health Canada for its norepinephrine bitartrate injection. This marks a historical achievement for the Company as it signifies the validation of J. Molner’s business processes in successfully developing and gaining regulatory approval for pharmaceutical products.

Mr. Jason Grenfell-Gardner, CEO of J. Molner AS, commented, “Today is a landmark day for everyone at J. Molner AS. This approval is not just a testament to the potential of our norepinephrine bitartrate injection but also an endorsement of J. Molner’s ability to navigate the complexities of drug development and regulatory pathways and our dedication to quality and innovation. This milestone underscores the efficacy of our strategies and advances our vision of building a new global specialty pharmaceutical company with Estonian roots.” Mr. Grenfell-Gardner commented.

Norepinephrine bitartrate is an essential medication indicated for the restoration and maintenance of blood pressure in all acute hypotensive or shock states which may result from surgery, trauma, hemorrhage, myocardial infarction, pheochromocytomectomy, sympathectomy, spinal anesthesia, septicemia, drug reactions, poliomyelitis, and blood transfusion reactions. The approval by Health Canada, one of the most stringent and respected regulatory bodies globally, is indicative of the drug’s quality, efficacy, and safety.

This product’s anticipated launch is scheduled for the third quarter of 2023.

         Jason Grenfell-Gardner
         
         J.Molner AS
         Member of the Management Board
         +372 536 00 346
         jason@jmolner.com